Windtree Therapeutics, Inc. 3Y Total Assets Growth (CAGR)

3Y Total Assets Growth (CAGR) of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including 3Y Total Assets Growth (CAGR) growth rates and interactive chart.


Highlights and Quick Summary

  • Annual 3Y Total Assets Growth (CAGR) for 2019 was 130.63% (a 234.26% increase from previous year)
  • Annual 3Y Total Assets Growth (CAGR) for 2018 was 39.08% (a -166.58% decrease from previous year)
  • Annual 3Y Total Assets Growth (CAGR) for 2017 was -58.7% (a 12.26% increase from previous year)
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical 3Y Total Assets Growth (CAGR) of Windtree Therapeutics, Inc.

Most recent 3Y Total Assets Growth (CAGR)of WINT including historical data for past 10 years.

Interactive Chart of 3Y Total Assets Growth (CAGR) of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. 3Y Total Assets Growth (CAGR) for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 130.63%
2018 39.08%
2017 -58.7%
2016 -52.29%
2015 14.01%
2014 52.76%
2013 83.16%

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.